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In this issue of Annals of Intensive care, Costa et  al. 
reported on the association between a lower erythrocyte 
superoxide dismutase (SOD)1 activity and the devel-
opment of acute kidney injury (AKI) in septic shock 
patients. At a given cutoff level, SOD1 was found to 
predict sepsis-induced AKI (SAKI) earlier than the clas-
sic KDIGO criteria. The authors suggested that erythro-
cyte SOD1 activity could act as an early marker of SAKI 
and, by extension, as a novel target of SAKI biomarker 
research [1]. The study results certainly are original and 
innovative, but questions arise when considering their 
impact.
First, how strong is the oxidative stress response asso-
ciated with SAKI? An honest answer is that we do not 
know! Sepsis indeed evolves along an inflammation–
ischemia–reperfusion scenario. An important hallmark 
of the disease, amongst others, is a devastating oxidative 
burst substantiated by a harsh combat opposing tissue-
aggressive reactive oxygen species (ROS) to intrinsic 
antioxidant body defense systems [2]. SAKI, however, is 
determined by a complex and highly treatment-depend-
ent interplay between inflammation, microcirculatory 
dysfunction, bioenergetic failure, and tubular cell adapta-
tion to injury [3]. Narrowing SAKI to a mere ischemia–
reperfusion disorder is a too excessive simplification of 
its pathophysiology. Moreover, ischemia–reperfusion-
induced oxidative stress is a generalized phenomenon, 
is difficult to quantify, and depends upon the duration of 
the ischemic insult and the speed of resuscitation both of 
which cannot be correctly estimated in the acute setting 
of sepsis. Erythrocyte SOD1 activity may thus be more an 
indicator of sepsis severity than of true kidney disease.
Second, is erythrocyte SOD1 an ideal biomarker? 
Arguably! Amidst the turmoil of oxidative aggres-
sion and antioxidant riposting, Costa et al. selected this 
particular scavenger probably because SOD is recog-
nized as one of the first-line antioxidant “firefighters.” 
By definition, an ideal biomarker is released by injured 
organ-specific cells, is rapidly and repeatedly measur-
able, exhibits plasma concentrations proportional to 
the extent of injury, allows evaluating ongoing or reced-
ing organ damage, and reacts to therapy. SOD hardly 
corresponds to any of these criteria. Mammals possess 
three SOD isoforms: a predominantly intracellular cop-
per–zinc SOD1, a mitochondrial manganese SOD2, and 
a copper–zinc SOD3 in the vascular extracellular space. 
Although catalyzing the same reaction, these isoforms 
are products of distinct genes and their specific subcel-
lular location results in compartmentalized redox signal-
ing. In fact, SOD2 might be a more specific marker than 
erythrocyte SOD1. SOD2 is abundantly present in the 
mitochondrial matrix where it is involved in dismutating 
superoxide anions generated by the respiratory enzyme 
chain [4]. Renal, and in particular proximal, tubular cells 
are extremely rich in mitochondria. The main pathophys-
iological phenotype of SAKI is tubular damage. Sepsis 
significantly cripples tubular cell integrity and function, 
which is reflected in the primarily tubuli-oriented quest 
for an adequate urinary SAKI biomarker [5, 6]. Changes 
in mitochondrial metabolism are increasingly thought to 
be a key issue for the progression of SAKI-related tubular 
damage. Dysfunctional mitochondria induce apoptosis 
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and generate ROS, whilst remaining exposed to external 
ROS harassment in case of severe or prolonged oxidative 
stress [7]. SOD2 might also be more useful for follow-up 
because it has a plasma half-life of 5–6 hours compared 
with 6–10 minutes for SOD1 [8]. Finally, it is conceivable 
that other enzymatic players implicated in the anti-oxi-
dative process (e.g., glutathione peroxidase and catalase) 
might equally well predict SAKI [9].
Thirdly, do the study results offer convincing evidence 
to pursue further research in this domain? Here, the 
answer is negative! An area under the receiver operating 
curve (AUROC) of 0.686 constitutes a rather weak cor-
relation between SOD1 activity and SAKI development 
[1]. Such equally low specificity/sensitivity profile was 
the main reason why, for instance, the use of the Clini-
cal Pulmonary Infection Score became heavily criticized 
for diagnosing ventilator-associated pneumonia [10]. To 
date, the urinary panel combining urinary insulin-like 
growth factor-binding protein 7 (IGFBP7) and tissue 
inhibitor of metalloproteinases-2 (TIMP-2) is consid-
ered to be the best performing biomarker set to predict 
the development of moderate or severe AKI. [TIMP-
2]*[IGFBP7] AUROC curves for prediction and risk 
stratification of SAKI largely exceeded 0.80 in critically ill 
septic patients with either low or high non-renal Sequen-
tial Organ Failure Assessment scores [11].
Intensive care nephrologists crave to abandon serum 
creatinine as a late, highly biased, and poorly predictive 
marker of SAKI for an early, reliable, and kidney-spe-
cific biomarker. Within this context, Costa et  al. pro-
vided interesting data of high scientific value. However, 
when “do not know,” “arguably” and “no” are the answers 
to pertinent questions regarding the clinical relevance 
of these findings, there is little reason to believe that a 
“novel avenue” of biomarker research in SAKI has been 
opened.
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